Sumatriptan succinate: Pharmacokinetics of different formulations in clinical practice

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 16, 2012, Pages 2369-2380

  Lionetto, Luana ^a   Negro, Andrea ^b,c   Casolla, Barbara ^a   Simmaco, Maurizio ^a   Martelletti, Paolo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

acute migraine; drug formulation; pharmacodynamics; pharmacokinetics; sumatriptan succinate

Indexed keywords

NAPROXEN; NP 101; PLACEBO; SEROTONIN 1 RECEPTOR; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; ZELRIX;

ACUTE MIGRAINE; APPLICATION SITE ERYTHEMA; APPLICATION SITE REACTION; CLINICAL PRACTICE; CLUSTER HEADACHE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SENSITIZATION; DRUG TOLERABILITY; DYSMENORRHEA; ERYTHEMA; FATIGUE; FIRST PASS EFFECT; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MALAISE; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL MIGRAINE; MIGRAINE; NAUSEA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHONOPHOBIA; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; SYSTEMATIC REVIEW (TOPIC); TABLET DISINTEGRATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANIMALS; CLUSTER HEADACHE; HUMANS; MIGRAINE DISORDERS; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 84867637384     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.730041     Document Type: Review

References (101)

1. Colman SS, Brod MI, Krishnamurthy A, et al. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001;23(1):127-45
2. Taylor FR. Migraine headache: Options for acute treatment. Curr Neurol Neurosci Rep 2005;5(2):86-92
3. Yang ZY, Le Y, Hu TT, et al. Production of ultrafine sumatriptan succinate particles for pulmonary delivery. Pharm Res 2008;25(9):2012-18
4. Dilone E, Bergstrom D, Cabana B, et al. Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. Sumatriptan Lingual Spray Study Group. Headache 2009;49(10):1445-53
5. Dahlof CG. Non-oral formulations of triptans and their use in acute migraine. Curr Pain Headache Rep 2005;9(3):206-12
6. Jain SA, Chauk DS, Mahajan HS, et al. Formulation and evaluation of nasal mucoadhesive microspheres of sumatriptan succinate. J Microencapsul 2009;26(8):711-21
7. Bigal ME, Bordini CA, Antoniazzi AL, et al. The Triptans formulations: A critical evaluation. Arq Neuropsiquiatr 2003;61(2-A):313-20
8. Tfelt-Hansen P, Edvinsson L. Pharmacokinetic and pharmacodynamic variability as possible causes for different drug responses in migraine. A comment. Cephalalgia 2007;27(10):1091-3 An excellent viewpoint on interindividual variability of triptan response.
9. Sheshala R, Khan N, Darwis Y. Formulation and optimization of orally disintegrating tablets of sumatriptan succinate. Chem Pharm Bull 2011;59(8):920-8
10. Shidhaye SS, Saindane NS, Sutar S, et al. Mucoadhesive bilayered patches for administration of sumatriptan succinate. AAPS PharmSciTech 2008;9(3):909-16
11. Balaguer-Fernandez C, Femenia-Font A, Del Rio-Sancho S, et al. Sumatriptan succinate transdermal delivery systems for the treatment of migraine. J Pharm Sci 2008;97(6):2102-9
12. Adelman JU, Adelman RD. Current options for the prevention and treatment of migraine. Clin Ther 2001;23(6):772-88
13. Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992;43(5):776-98
14. Asghar MS, Hansen AE, Kapijimpanga T, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology 2010;75(17):1520-6
15. Jeong HJ, Chenu D, Johnson EE, et al. Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey. Mol Pain 2008;4:54
16. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995;47(6):543-8
17. Fuseau E, Petricoul O, Moore KH, et al. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002;41(11):801-11
18. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 1994;47(7):1253-7
19. Dixon CM, Saynor DA, Andrew PD, et al. Disposition of sumatriptan in laboratory animals and humans. Drug Metab Dispos 1993;21(5):761-9
20. Fowler PA, Thomas M, Lacey LF, et al. Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. Cephalalgia 1989;9(Suppl 9):57-62
21. Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: The clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs 2010;24(11):929-40
22. Ferrari A, Pinetti D, Bertolini A, et al. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur J Clin Pharmacol 2008;64(5):489-95
23. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47(4):622-51
24. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2:CD008615 A systematic review on oral sumatriptan.
25. Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2:CD009663 A systematic review on intranasal sumatriptan.
26. Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2. [Epub ahead of print] A systematic review on subcutaneous sumatriptan.
27. Derry CJ, Derry S, Moore RA. Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2. [Epub ahead of print] A systematic review on rectal sumatriptan.
28. Jelinski SE, Becker WJ, Christie SN, et al. Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neurol Sci 2006;33(1):73-9
29. Hodge JA, Hodge KD. Ischemic colitis related to sumatriptan overuse. J Am Board Fam Med 2010;23(1):124-7
30. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001;358(9294):1668-75 Overview comparing the major therapeutical endpoints of various triptans.
31. O'Quinn S, Davis RL, Gutterman DL, et al. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999;19(4):223-31
32. Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002;112(2):135-40
33. Christoph-Diener H, Ferrari M, Mansbach H; SNAP Database Study Group. Predicting the response to sumatriptan: The Sumatriptan Naratriptan Aggregate Patient Database. Neurology 2004;63:520-4
34. Weidmann E, Unger J, Blair S, et al. An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations. Clin Ther 2003;25:235-46
35. Tepper SJ, Cady R, Dodick D, et al. Oral sumatriptan for the acute treatment of probable migraine: First randomized, controlled study. Headache 2006;46:115-24
36. Tfelt-Hansen P, Bach FW, Daugaard D, et al. Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: A randomised, double-blind, placebo-controlled study. J Headache Pain 2006;7:389-94
37. Savani N, Pfaffenrath V, Rice L, et al. Efficacy, tolerability, and patient satisfaction with 50-and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets. Clin Ther 2001;23:260-71
38. Burstein R, Jakubowski M, Collins B. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol 2004;55:19-26
39. Aurora SK, Barrodale PM, McDonald SA, et al. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache 2009;49:1001-4
40. Cady RK, Rubino J, Crummett D, et al. Oral sumatriptan in the treatment of recurrent headache. Arch Fam Med 1994;3:766-72
41. Rapoport AM, Visser WH, Cutler NR, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology 1995;45:1505-9
42. Walls C, Lewis A, Bullman J, et al. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 2004;20:803-9
43. Sheftell FD, Dahlof CG, Brandes JL, et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fastdisintegrating/ rapid-release formulation of sumatriptan tablets. Clin Ther 2005;27:407-17
44. Newman LC, Cady RK, Landy S, et al. Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan. Int J Clin Pract 2008;62:1889-99
45. Barbanti P, Carpay JA, Kwong WJ, et al. Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. Curr Med Res Opin 2004;20:2021-9
46. Landy SH, McGinnis JE, McDonald SA. Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan. Headache 2005;45:346-9
47. Wendt J, Cady R, Singer R, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther 2006;28:517-26
48. Linde M, Mellberg A, Dahlof C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 2006;26:113-21
49. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology 1994;44:1587-92
50. Burke-Ramirez P, Asgharnejad M, Webster C, et al. Efficacy and tolerability of subcutaneous sumatriptan for acute migraine: A comparison between ethnic groups. Headache 2001;41:873-82
51. Cady RK, Dexter J, Sargent JD, et al. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 1993;43:1363-8
52. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: Results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000;75:782-9
53. Freitag FG. Sumatriptan needle-free subcutaneous (Sumavel(?) DosePro?) approved for the acute treatment of migraine, with or without aura, and cluster headaches. Expert Rev Neurother 2011;11:481-90
54. Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): Bioequivalence and ease of use. Headache 2009;49:1435-44
55. Rothrock JF, Cady RK, Aurora SK, et al. Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: Efficacy and impact on patient-rated functionality, satisfaction, and confidence. Curr Med Res Opin 2011;27:2185-91
56. Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine. Neurology 1997;49:1225-30
57. Farmer K, Cady R, Bleiberg J, et al. Sumatriptan nasal spray and cognitive function during migraine: Results of an open-label study. Headache 2001;41:377-84
58. Rothner AD, Winner P, Nett R, et al. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: Results of a multicenter, open-label study. Clin Ther 2000;22:1533-46
59. Carpay JA, Linssen WH, Koehler PJ, et al. Efficacy of sumatriptan nasal spray in recurrent migrainous headache: An open prospective study. Headache 2003;43:395-9
60. Docekal P, Bartlova L, Ehler E, et al. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. Cephalalgia 2010;30:933-42
61. Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000;106:989-97
62. Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: A randomized, double-blind, placebo-controlled, acute study. Headache 2006;46:212-22
63. Ahonen K, Hamalainen ML, Rantala H, et al. Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. Neurology 2004;62:883-7
64. Pakalnis A, Kring D, Paolicchi J. Parental satisfaction with sumatriptan nasal spray in childhood migraine. J Child Neurol 2003;18:772-5
65. Goldstein J, Smith TR, Pugach N, et al. A Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 2012. [Epub ahead of print]
66. Pierce M, Marbury T, O'Neill C, et al. Zelrix: A novel transdermal formulation of sumatriptan. Headache 2009;49:817-25
67. Dodick DW, Rozen TD, Goadsby PJ, et al. Cluster headache. Cephalalgia 2000;20:787-803
68. Monstad I, Krabbe A, Micieli G, et al. Preemptive oral treatment with sumatriptan during a cluster period. Headache 1995;35:607-13
69. The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991;325:322-6
70. Ekbom K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: A dose comparison study. The Sumatriptan Cluster Headache Study Group. Acta Neurol Scand 1993;88:63-9
71. Gobel H, Lindner V, Heinze A, et al. Acute therapy for cluster headache with sumatriptan: Findings of a one-year-longterm study. Neurology 1998;51:908-11
72. Gregor N, Schlesiger C, Akova-Ozturk E, et al. Treatment of cluster headache attacks with less than 6 mg subcutaneous sumatriptan. Headache 2005;45:1069-72
73. Hardebo JE. Subcutaneous sumatriptan in cluster headache: A time study of the effect on pain and autonomic symptoms. Headache 1993;33:18-21
74. Rossi P, Lorenzo GD, Formisano R, et al. Subcutaneous sumatriptan induces changes in frequency pattern in cluster headache patients. Headache 2004;44:713-18
75. Hering-Hanit R. Alteration in nature of cluster headache during subcutaneous administration of sumatriptan. Headache 2000;40:41-4
76. Ekbom K, Waldenlind E, Cole JA, et al. Sumatriptan in chronic cluster headache: Results of continuous treatment for eleven months. Cephalalgia 1992;12:254-6
77. Centonze V, Rossi A, Causarano V, et al. Sumatriptan overuse in episodic cluster headache: Lack of adverse events, rebound syndromes, drug dependance and tachyphylaxis. Funct Neurol 2000;15:167-70
78. Serdar Turhal N. Sumatriptan overdose in episodic cluster headache: A case report of overuse without event. Cephalalgia 2001;21:700
79. Kallweit U, Sandor PS. Sumatriptan in excessive doses over 15 years in a patient with chronic cluster headache. Headache 2011;51:1546-8
80. Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine: A review of clinical studies. Cephalalgia 1999;19:769-78
81. Ashford E, Salonen R, Saiers J, et al. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia 1998;18:273-7
82. Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine: A review of clinical studies. Cephalalgia 1999;19:769-78
83. Winner P, Saper JR, Nett R, et al. Sumatriptan nasal spray in the acute treatment of migraine in adolescent migraineurs. Pediatrics 1999;104:694-5
84. Schuh-Hofer S, Reuter U, Kinze S, et al. Treatment of acute cluster headache with 20 mg sumatriptan nasal spray: An open pilot study. J Neurol 2002;249:94-9
85. Hardebo JE, Dahlof C. Sumatriptan nasal spray (20 mg/dose) in the acute treatment of cluster headache. Cephalalgia 1998;18:487-9
86. van Vliet JA, Bahra A, Martin V, et al. Intranasal sumatriptan in cluster headache: Randomized placebo-controlled double-blind study. Neurology 2003;60:630-3
87. Johannes CB, Linet MS, Stewart WF, et al. Relationship of headache to phase of the menstrual cycle among young women: A daily dairy study. Neurology 1995;45:1076-82
88. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004;24:707-16
89. Nett R, Landy S, Shackelford S, et al. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003;102:835-42
90. Schreiber CP, Cady RK. Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg. Clin Ther 2007;29(Suppl):2511-19
91. Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: A prospective, placebo-controlled study with oral sumatriptan. J Headache Pain 2005;6:81-7
92. Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 1998;51:307-9
93. Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: Two randomized controlled trials. Obstet Gynecol 2009;114:106-13
94. Cady RK, Diamond ML, Diamond MP, et al. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: Satisfaction, productivity, and functional disability outcomes. Headache 2011;51:664-73
95. Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol 1993;82:769-72
96. Facchinetti F, Bonellie G, Kangasniemi P, et al. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obstet Gynecol 1995;86:911-16
97. Facchinetti F, Allais G, Nappi RE, et al. Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: A pilot study. Gynecol Endocrinol 2010;26:773-9
98. Tfelt-Hansen P, Le H. Calcitonin gene-related peptide in blood: Is it increased in the external jugular vein during migraine and cluster headache? A review. J Headache Pain 2009;10:137-43
99. Tfelt-Hansen PC. Does sumatriptan cross the blood-brain barrier in animals and man? J Headache Pain 2010;11:5-12 . Re-thinking on old and new properties of sumatriptan.
100. Mitsikostas DD, Knight YE, Lasalandra M, et al. Triptans attenuate capsaicin-induced CREB phosphorylation within the trigeminal nucleus caudalis: A mechanism to prevent central sensitization? J Headache Pain 2011;12:411-17
101. Asghar MS, Hansen AE, Larsson HB, et al. Effect of CGRP and sumatriptan on the BOLD response in visual cortex. J Headache Pain 2012;13:159-66